Asensus Surgical Announces Leading United States-Based Hospital to Initiate Senhance Surgery Program
RESEARCH TRIANGLE PARK, N.C., July 14, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™(PGS), today announced that a leading United States-based hospital, has initiated a Senhance Surgical System program for use within their pediatric surgery department. The initiation of the Senhance program marks an important milestone as this represents the first system to be exclusively utilized by pediatric surgeons at a United States-based hospital, showcasing Senhance’s unique applicability for pediatric applications. We expect to provide further information in the next 60 days.
“We are thrilled to collaborate and introduce our Senhance Surgical System to this esteemed pediatric surgery program,” said Anthony Fernando, Asensus Surgical President, and CEO. “The collaboration highlights the shared commitment to innovation and patient-centric care. Together, we will strive to drive advancements in surgical techniques, ultimately improving the lives of children requiring surgery.”
The Senhance Surgical System, empowered by the Intelligent Surgical Unit™ (ISU™), represents a breakthrough in digital surgical platforms, leveraging augmented intelligence and machine learning for superior surgical performance and patient outcomes with features such as haptic feedback, eye-tracking camera control, and 3D visualization. Notably, its specialized 3mm instruments are perfectly suited for the delicate nature of pediatric procedures.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of Digital Laparoscopy and the Senhance Surgical System, the Company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery, Digital Laparoscopy with the Senhance Surgical System and the new LUNA System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Forward-Looking Statements This press release includes statements relating to the Senhance Surgical System and a leading United States-based hospital initiating a program with the Senhance Surgical System. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the collaboration with the leading US-based pediatric hospital focusing on pediatric applications will be successful and whether the collaboration will be able to drive advancements in surgical techniques and achieve optimal results for young patients. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT: Mark Klausner or Mike Vallie ICR Westwicke invest@asensus.com 443-213-0499
MEDIA CONTACT: Dan Ventresca Matter Communications AsensusPR@matternow.com 617-874-5488 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/21c5e973-55e5-4390-bb1c-5a977f6b35c7
